Document is current
Any future updates will be listed below
-
Authors
Wortman, Juliana C.
He, Ting-Fang https://orcid.org/0000-0001-5374-0713
Solomon, Shawn https://orcid.org/0000-0002-3819-9436
Zhang, Robert Z.
Rosario, Anthony
Wang, Roger https://orcid.org/0000-0003-3401-9861
Tu, Travis Y. https://orcid.org/0000-0002-8167-313X
Schmolze, Daniel https://orcid.org/0000-0002-6947-2546
Yuan, Yuan
Yost, Susan E. https://orcid.org/0000-0002-9422-0316
Li, Xuefei
Levine, Herbert https://orcid.org/0000-0002-8819-9055
Atwal, Gurinder
Lee, Peter P. https://orcid.org/0000-0002-2660-4377
Yu, Clare C. https://orcid.org/0000-0002-6565-2988
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer
V Foundation for Cancer Research
Breast Cancer Research Foundation
National Science Foundation (PHY-1607611)
Cure Breast Cancer Foundation
- License Information
-
More Information
Article History
Received: 13 November 2020
Accepted: 3 June 2021
First Online: 1 July 2021
Competing interests
: Y.Y. has contracted clinical trials and research projects sponsored by Merck, Eisai, Novartis, Genentech, and Pfizer. After contributing to this study, G.A. moved to Regeneron from Cold Spring Harbor Laboratory. The other authors declare that they have no competing interests.
